We caught up with Ronald van Vollenhoven (Amsterdam University Medical Centers, Amsterdam, the Netherlands) to discuss the use of ustekinumab in patients with active systemic lupus erythematosus (Clinical Trial Identifier: NCT02349061). The abstract ‘Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study’ (ABSTRACT NUMBER: 1826) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is the rationale for the use of ustekinumab in the treatment of systemic lupus erythematosus (SLE)? (0:26)
- Could you tell us a little about the Phase 2 study you are presenting, and its findings? (1:31)
- What are the challenges in selecting clinical endpoints for SLE studies? (3:15)
- What were the strengths and limitations of this study? (4:28)
- How will these findings inform future research? (5:50)
Disclosures: Research Support (institutional grants): BMS, GSK, Lilly, UCB. Support for Educational programs (institutional grants): Pfizer, Roche. Consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB. Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Systemic Lupus Erythematosus
Cynthia Aranow, ACR 2021: Subcutaneous Belimumab and Rituximab Sequential Therapy in Systemic Lupus Erythematosus
It was a pleasure to speak with Professor Cynthia Aranow (Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA) around the BLISS-BELIEVE study, investigating sequential belimumab and rituximab therapy in SLE (NCT03312907). This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American […]
Susan Manzi, ACR 2021: Efficacy of Anifrolumab by Baseline Therapy is SLE
It was a pleasure to discuss with Dr Susan Manzi (Allegheny Health Network Medicine Institute, Pittsburgh, PA, USA) the recent post-hoc analysis designed to assess the efficacy of anifrolumab by baseline therapy. This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of […]
Ronald Van Vollenhoven, ACR 2021: Post Hoc Analysis of BIIB059 in Systemic Lupus Erythematosus
It was a pleasure to speak with Professor Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss his post hoc analysis of the LILAC clinical trial, investigating BIIB059 in participants with systemic lupus erythematosus (NCT02847598). This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!